Vitiligo Drugs Market, by Drug Class (Calcineurin Inhibitors, Corticosteroids, and Psoralens), by Type (Segmental and Non-segmental), by Route of Administration (Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Onlin

Vitiligo Drugs Market, by Drug Class (Calcineurin Inhibitors, Corticosteroids, and Psoralens), by Type (Segmental and Non-segmental), by Route of Administration (Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Vitiligo is a disease that causes loss of skin colour in patches. The discoloured areas usually get bigger with time. The condition usually affects the skin on any part of the body. It can also affect hair and the inside of the mouth. The colour of hair and skin is determined by melanin. Melanin is a natural skin pigment; skin, eye, and hair color in people and animal depends on type and amount of melanin. Vitiligo occurs, when cells that produce melanin stop functioning. The condition is not life- threatening or transferable. There are two major categories of vitiligo disease such as segmental vitiligo and non-segmental vitiligo. Some of the major symptoms of vitiligo disease includes patchy loss of skin colour, which mostly appears on hands and face. Premature whitening of the hair on your scalp or eyebrows. Loss in the colour inside the mouth. Vitiligo disease can be treated by medications such as calcineurin inhibitors, corticosteroids, Psoralens. Vitiligo disease is also treated by surgery.
Market Dynamics
Agreement and collaboration by major players to develop drug is expected to propel growth of the global vitiligo drug market during the forecast period. For instance, in October 2018, Boston Pharmaceutical announced the agreement with GlaksoSmith Kline for development of phase 1 pipeline drug GSK3183475, a small molecule inhibitor used in treatment of vitiligo and psoriasis.
However, alternative therapies for vitiligo treatment is expected to limit the market growth. For instance, combination therapy of psoralen and light therapy. The treatment combines the use of a plant- derived molecule called psoralen and light therapy for treating vitiligo. The patient is exposed to ultraviolet light after ingesting psoralen. The total span of treatment ranges between 3 weeks to 12 months.
Key features of the study:
This report provides in-depth analysis of the global vitiligo drug market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global lung cancer screening market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd., Bristol- Myers Squibb, Pfizer, Inc., Clinuvel Pharmaceuticals Ltd., Boston Pharmaceuticals, Applied Biology, Inc., Arcutis Biotherapeutics, Villaris Therapeutics, Arrien Pharmaceuticals LLC, and Temprian Therapeutics Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global vitiligo drug market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for vitiligo drug market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Vitiligo Drug Market, By Drug Type:
Marketed Drugs
Calcineurin Inhibitors
Corticosteroids
Psoralens
Pipeline Drug
Ruxolitinib (Phase 3)
Global Vitiligo Drug Market, By Indication Type:
Segmental Vitiligo
Non-segmental Vitiligo
Global Vitiligo Drug Market, By Route of Administration Type:
Oral
Topical
Global Vitiligo Drug Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Vitiligo Drug Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Marketed Drugs
Calcineurin Inhibitors
Corticosteroids
Psoralens
Pipeline Drug
Ruxolitinib (Phase 3)
By Indication Type:
Segmental Vitiligo
Non-segmental Vitiligo
By Route of Administration
Oral
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Marketed Drugs
Calcineurin Inhibitors
Corticosteroids
Psoralens
Pipeline Drug
Ruxolitinib (Phase 3)
By Indication Type:
Segmental Vitiligo
Non-segmental Vitiligo
By Route of Administration
Oral
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Marketed Drugs
Calcineurin Inhibitors
Corticosteroids
Psoralens
Pipeline Drug
Ruxolitinib (Phase 3)
By Indication Type:
Segmental Vitiligo
Non-segmental Vitiligo
By Route of Administration
Oral
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Marketed Drugs
Calcineurin Inhibitors
Corticosteroids
Psoralens
Pipeline Drug
Ruxolitinib (Phase 3)
By Indication Type:
Segmental Vitiligo
Non-segmental Vitiligo
By Route of Administration
Oral
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Marketed Drugs
Calcineurin Inhibitors
Corticosteroids
Psoralens
Pipeline Drug
Ruxolitinib (Phase 3)
By Indication Type:
Segmental Vitiligo
Non-segmental Vitiligo
By Route of Administration
Oral
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Marketed Drugs
Calcineurin Inhibitors
Corticosteroids
Psoralens
Pipeline Drug
Ruxolitinib (Phase 3)
By Indication Type:
Segmental Vitiligo
Non-segmental Vitiligo
By Route of Administration
Oral
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Dermavant Sciences, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Incyte Corporation
Aclaris Therapeutics, Inc
Reddy’s Laboratories Ltd.
Bristol - Myers Squibb
Pfizer, Inc.
Clinuvel Pharmaceuticals Ltd.
Boston Pharmaceuticals
Applied Biology, Inc.
Arcutis Biotherapeutics
Villaris Therapeutics
Arrien Pharmaceuticals LLC
Temprian Therapeutics Inc.
“*” marked represents similar segmentation in other categories in the respective section.